Lateral hypothalamus involvement in control of stress response by bed nucleus of the stria terminalis endocannabinoid neurotransmission in male rats

Lucas Gomes-de-Souza1,2, Willian Costa-Ferreira1,2, Michelle M. Mendonça3, Carlos H. Xavier3 & Carlos C. Crestani1,2,4*

The endocannabinoid neurotransmission acting via local CB1 receptor in the bed nucleus of the stria terminalis (BNST) has been implicated in behavioral and physiological responses to emotional stress. However, the neural network related to this control is poorly understood. In this sense, the lateral hypothalamus (LH) is involved in stress responses, and BNST GABAergic neurons densely innervate this hypothalamic nucleus. However, a role of BNST projections to the LH in physiological responses to stress is unknown. Therefore, using male rats, we investigated the role of LH GABAergic neurotransmission in the regulation of cardiovascular responses to stress by CB1 receptors within the BNST. We observed that microinjection of the selective CB1 receptor antagonist AM251 into the BNST decreased the number of Fos-immunoreactive cells within the LH of rats submitted to acute restraint stress. Treatment of the BNST with AM251 also enhanced restraint-evoked tachycardia. Nevertheless, arterial pressure increase and sympathetically-mediated cutaneous vasoconstriction to restraint was not affected by CB1 receptor antagonism within the BNST. The effect of AM251 in the BNST on restraint-evoked tachycardia was abolished in animals pretreated with the selective GABAA receptor antagonist SR95531 in the LH. These results indicate that regulation of cardiovascular responses to stress by CB1 receptors in the BNST is mediated by GABAergic neurotransmission in the LH. Present data also provide evidence of the BNST endocannabinoid neurotransmission as a mechanism involved in LH neuronal activation during stressful events.

The bed nucleus of the stria terminalis (BNST) has been implicated in physiological and behavioral responses to stress1-3. Regarding the cardiovascular responses, previous studies demonstrated that BNST modulates the blood pressure and heart rate (HR) increases caused by both unconditioned and conditioned stressfull stimuli, as well as by non-aversive environmental challenges (e.g., exercise)4-6.

Several neurochemical mechanisms have been implicated in the BNST control of stress responses1-7, including the endocannabinoid system8. Indeed, the presence of endocannabinoid receptors and enzymes involved in endocannabinoid synthesis and degradation were identified within the BNST9-15. Activation of BNST endocannabinoid neurotransmission during aversive threats was first evidenced by demonstration that systemic administration of a selective CB1 receptor antagonist enhanced BNST neuronal activation evoked by stress16,17. Accordingly, recent studies identified a role of BNST CB1 receptors in anxiogenic responses to stress11,18. We also reported an inhibitory influence of CB1 receptors present in the BNST in tachycardia observed during acute restraint stress13. Taken together, these results indicated the BNST endocannabinoid neurotransmission as part of the neural pathway regulating stress responses. However, the neural circuit related to this control is unknown.

1Laboratory of Pharmacology, School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, São Paulo, Brazil. 2Joint UFSCar-UNESP Graduate Program in Physiological Sciences, São Carlos, São Paulo, Brazil. 3Institute of Biological Sciences, Federal University of Goiás, Goiânia, Goiás, Brazil. 4Laboratory of Pharmacology, Department of Department of Drugs and Pharmaceutics, School of Pharmaceutical Sciences, São Paulo State University - UNESP, Rodovia Araraquara-Jau Km 01 (Campus Universitário), Campus Ville, Araraquara, SP 14800-903, Brazil. *email: cccrestani@yahoo.com.br
The BNST is proposed as an important site connecting corticolimbic structures with effector nuclei of physiological and behavioral responses in the hypothalamus and brainstem. In this sense, the BNST sends dense projections to the lateral hypothalamus (LH). Such as BNST, the LH also plays a role in physiological and behavioral responses to emotional stress. Regarding the stress-evoked cardiovascular responses, previous studies documented a role of this diencephalic region controlling cardiovascular responses evoked by both conditioned and unconditioned aversive stimuli. The LH has an inhibitory influence in cardiovascular responses to unconditioned stress, which is mediated by a balance of local excitatory and inhibitory inputs. Indeed, local LH treatment with a selective NMDA glutamatergic receptor antagonist enhanced the HR response to restraint stress, whereas opposite effect was observed following LH treatment with a selective GABA<sub>A</sub> receptor antagonist.

The majority of neurons within the BNST present a GABAergic phenotype. Accordingly, some studies provided evidence of GABAergic inputs within the LH arising from the BNST. These morphofunctional evidence, together with evidence stated above of an inhibitory role of LH in tachycardia restraint, supported the idea that the LH might be part of the neural pathway related to the inhibitory control of restraint-evoked tachycardia by BNST endocannabinoid neurotransmission. In this sense, considering recent evidence that regulation of restraint-evoked tachycardia by BNST CB<sub>1</sub> receptor is mediated by inhibition of local glutamatergic neurotransmission, we investigated the hypothesis that the antagonism of CB<sub>1</sub> receptor within the BNST decreases the skin temperature (time factor: F(6,144) = 53, P < 0.0001) (Fig. 3). Two-way ANOVA also indicated effect of BNST and/or LH pharmacological treatments on restraint-evoked HR increase (F(3,24) = 4.0, P = 0.0198), but without affecting MAP (F(3,24) = 0.4, P = 0.7551) (Fig. 2). A treatment × time interaction for HR (F(105,840) = 2.4, P < 0.0001) and MAP (F(105,840) = 1.5, P = 0.0042) was also evidenced. Post-hoc analysis revealed that AM251 into the BNST decreased the number of Fos-positive cells in the LH following exposure to restraint stress (t = 4.59; df = 17, P = 0.0003), when compared to vehicle-treated animals (100 nL/side, n = 8) (Fig. 1). Figure 1 also presents representative coronal sections of the LH region showing Fos-positive cells of animals subjected to restraint stress that received vehicle or AM251 into the BNST, as well as a representative section indicating the LH location.

### Results

#### Effect of CB<sub>1</sub> receptor blockade within the BNST on number of Fos-positive neurons in the LH of stressed animals.

Bilateral microinjection of the selective CB<sub>1</sub> receptor antagonist AM251 (100 pmol/100 nL/side, n = 11) into the BNST decreased the number of Fos-positive cells in the LH following restraint stress (t = 4.59; df = 17, P = 0.0003). Measurements were done at 30 and 60 min, when compared to vehicle-treated animals (100 nL/side, n = 8) (Fig. 3). A two-way ANOVA also indicated effect of BNST and/or LH pharmacological treatments on restraint-evoked HR increase (F(3,24) = 4.0, P = 0.0198), but without affecting MAP (F(3,24) = 0.4, P = 0.7551) (Fig. 2). A treatment × time interaction for HR (F(105,840) = 2.4, P < 0.0001) and MAP (F(105,840) = 1.5, P = 0.0042) was also evidenced. Post-hoc analysis revealed that AM251 into the BNST decreased the number of Fos-positive cells in the LH following exposure to restraint stress (t = 4.59; df = 17, P = 0.0003), when compared to vehicle-treated animals (100 nL/side, n = 8) (Fig. 1). Figure 1 also presents representative coronal sections of the LH region showing Fos-positive cells of animals subjected to restraint stress that received vehicle or AM251 into the BNST, as well as a representative section indicating the LH location.

#### Effect of GABA<sub>A</sub> receptor antagonist in the LH in changes on arterial pressure and HR reactivity to acute restraint stress evoked by CB<sub>1</sub> receptor blockade in the BNST.

Analysis of basal parameters (i.e., pre-stress values) indicated that bilateral microinjections of the GABA<sub>A</sub> receptor antagonist SR95531 (1 pmol/100 nL/side) into the LH and/or the selective CB<sub>1</sub> receptor antagonist AM251 (100 pmol/100 nL/side) into the BNST affected mean arterial pressure (MAP) (F(3,24) = 3.3, P = 0.0376), but without changing HR (F(3,24) = 0.5, P = 0.7259) (Table 1). Nevertheless, analysis of the time-course curves indicated that acute restraint stress caused a sustained increase on both HR (F(3,24) = 4.7, P = 0.0103) and MAP (F(3,24) = 0.4, P = 0.7553) (Fig. 2). A two-way ANOVA also indicated effect of BNST and/or LH pharmacological treatments on restraint-evoked HR increase (F(3,24) = 4.0, P = 0.0198), but without affecting MAP (F(3,24) = 0.4, P = 0.7551) (Fig. 2). A treatment × time interaction for HR (F(105,840) = 2.4, P < 0.0001) and MAP (F(105,840) = 1.5, P = 0.0042) was also evidenced. Post-hoc analysis revealed that AM251 into the BNST (saline LH + AM251 BNST group) increased restraint-evoked tachycardia response (P = 0.0077) (Fig. 2). The effect of AM251 within the BNST on HR increase to restraint stress was inhibited by LH pretreatment with the GABA<sub>A</sub> receptor antagonist (SR95531 LH + AM251 BNST group) (P = 0.3898) (Fig. 2).Post-hoc analysis did not reveal specific differences between the experimental groups on MAP response (P > 0.05) (Fig. 2).

#### Effect of CB<sub>1</sub> receptor blockade within the BNST on number of Fos-positive neurons in the LH of stressed animals.

Bilateral microinjection of the selective CB<sub>1</sub> receptor antagonist AM251 (100 pmol/100 nL/side, n = 11) into the BNST decreased the number of Fos-positive cells in the LH following exposure to restraint stress (t = 4.59; df = 17, P = 0.0003), when compared to vehicle-treated animals (100 nL/side, n = 8) (Fig. 1). Figure 1 also presents representative coronal sections of the LH region showing Fos-positive cells of animals subjected to restraint stress that received vehicle or AM251 into the BNST, as well as a representative section indicating the LH location.

#### Effect of GABA<sub>A</sub> receptor antagonist in the LH in changes on arterial pressure and HR reactivity to acute restraint stress evoked by CB<sub>1</sub> receptor blockade in the BNST.

Analysis of basal parameters (i.e., pre-stress values) indicated that bilateral microinjections of the GABA<sub>A</sub> receptor antagonist SR95531 (1 pmol/100 nL/side) into the LH and/or the selective CB<sub>1</sub> receptor antagonist AM251 (100 pmol/100 nL/side) did not affect the basal values (i.e., pre-stress level). Analysis of the time-course curves indicated that acute restraint stress caused a sustained increase on both HR (F(3,24) = 4.7, P = 0.0103), but without affecting MAP (F(3,24) = 0.4, P = 0.7553) (Fig. 2). Post-hoc analysis revealed that AM251 into the BNST (saline LH + AM251 BNST group) increased tachycardia response (P = 0.0042), and such potentiation effect was absent in animals pretreated with the GABA<sub>A</sub> receptor antagonist in the LH (SR95531 LH + AM251 BNST group) (P = 0.4760) (Fig. 2).

Figure 2 presents representative experimental recordings showing the effect of restraint stress in MAP and HR in animals that received vehicle or the selective GABA<sub>A</sub> receptor antagonist into the LH, followed by microinjection of vehicle or the CB<sub>1</sub> receptor antagonist into the BNST.

#### Effect of GABA<sub>A</sub> receptor antagonist in the LH in changes on tail skin temperature reactivity to acute restraint stress evoked by CB<sub>1</sub> receptor blockade in the BNST.

Bilateral microinjections of the GABA<sub>A</sub> receptor antagonist SR95531 (1 pmol/100 nL/side) into the LH and/or the selective CB<sub>1</sub> receptor antagonist AM251 (100 pmol/100 nL/side) did not affect the basal values (i.e., pre-stress level) of tail skin temperature (F(3,24) = 1.9, P = 0.1656) (Table 1). However, analysis of the time-course curves indicated that acute restraint stress decreased the skin temperature (time factor: F(6,144) = 53, P < 0.0001) (Fig. 3). A two-way ANOVA also indicated effect of BNST and/or LH pharmacological treatments on restraint-evoked decrease in tail skin temperature (F(3,24) = 1.8, P = 0.1847) (Fig. 3), but a treatment × time interaction was evidenced (F(18,144) = 3.1, P = 0.0059). Nevertheless, post-hoc analysis did not reveal differences between the experimental groups in restraint-evoked drop in tail skin temperature (P > 0.05) (Fig. 3). Analysis of the mean change during the entire restraint period also did not indicate effect of pharmacological treatments on tail skin temperature response (F(3,24) = 2.9, P = 0.0515) (Fig. 3). Figure 3 presents representative images showing the tail skin temperature before and after restraint stress.
Figure 1. Effect of bed nucleus of the stria terminalis (BNST) treatment with the CB1 receptor antagonist AM251 in the number of Fos-immunoreactive (IR) cells in the LH following exposure to a 60-min session of restraint stress. (Top) Representative coronal sections showing Fos-IR cells in the LH following restraint stress exposure in animals that received bilateral microinjection of vehicle or AM251 into the BNST (bottom), as well as a representative section indicating the LH location (top). 3V third ventricle, LH lateral hypothalamus, PVN paraventricular nucleus of the hypothalamus. (Bottom) Number of Fos-IR cells in the LH following exposure to acute restraint stress in animals treated with vehicle [solution of saline containing 30% of DMSO (DMSO), 100 nL, n = 8] (white bar) or the selective CB1 receptor antagonist AM251 (100 pmol/100 nL, n = 11) (green bar) into the BNST. The bars represent the mean ± SEM. * P < 0.05, Student’s t test.

Table 1. Basal parameters of mean arterial pressure (MAP), heart rate (HR) and tail skin temperature (T) after pharmacological treatment of the BNST with the selective CB1 receptor antagonist AM251 (or vehicle) and/or the LH with the selective GABA<sub>A</sub> receptor antagonist SR95531 (or vehicle). Values are mean ± SEM, one-way ANOVA. DMSO saline containing 30% of DMSO, SAL saline, SR SR95531.
and during restraint stress in animals that received vehicle or the selective GABA_A receptor antagonist into the LH, followed by microinjection of vehicle or the CB1 receptor antagonist into the BNST.

Discussion
The present results indicate for the first the LH as part of the neural pathway regulating physiological responses during stressful events by the BNST. In fact, we observed that BNST treatment with the selective CB1 receptor antagonist AM251 into the bed nucleus of the stria terminalis (BNST) in arterial pressure and heart rate (HR) changes evoked by an acute session of restraint stress. (Top, left) Time-course curves of changes on mean arterial pressure (Δ MAP) and HR (Δ HR) evoked by acute restraint stress in animals treated bilaterally into the LH with saline (SAL, 100 nL) or the selective GABA_A receptor antagonist SR95531 (1 pmol/100 nL), followed by a second microinjection into the BNST of vehicle [solution of saline containing 30% of DMSO (DMSO), 100 nL] or the selective CB1 receptor antagonist AM251 (AM251, 100 pmol/100 nL). Circles represent the mean ± SEM. *P < 0.05 over the entire restraint period compared to SAL LH + DMSO BNST group. Two-way ANOVA accompanied by Bonferroni post-hoc test (n = 7/group).

(Top, right) Mean Δ MAP and Δ HR during the entire restraint stress period in animals treated bilaterally into the LH with SAL (100 nL) or SR95531 (1 pmol/100 nL), followed by a second microinjection into the BNST of DMSO (100 nL) or AM251 (100 pmol/100 nL). Columns represent the mean and bars the SEM. *P < 0.05 in relation to SAL LH + DMSO BNST group. One-way ANOVA accompanied by Bonferroni post-hoc test (n = 7/group).

(Bottom) Pulsatile arterial pressure (PAP), MAP and HR recordings before and during restraint stress of representative rats illustrating the effect of local LH treatment with saline (SAL) or the selective GABA_A receptor antagonist SR95531, followed by a second microinjection into the BNST of vehicle (DMSO) or the selective CB1 receptor antagonist AM251 (AM251). The arrows indicate the microinjection into the LH and BNST, respectively. Note the increase in restraint-evoked tachycardia in SAL LH + AM251 BNST group, which was inhibited when the LH was pretreated with the GABA_A receptor antagonist (SR95531 LH + AM251 BNST group).

Figure 2. Effect of lateral hypothalamus (LH) treatment with the selective GABA_A receptor antagonist SR95531 and/or microinjection of the CB1 receptor antagonist AM251 into the bed nucleus of the stria terminalis (BNST) in arterial pressure and heart rate (HR) changes evoked by an acute session of restraint stress. (Top, left) Time-course curves of changes on mean arterial pressure (Δ MAP) and HR (Δ HR) evoked by acute restraint stress in animals treated bilaterally into the LH with saline (SAL, 100 nL) or the selective GABA_A receptor antagonist SR95531 (1 pmol/100 nL), followed by a second microinjection into the BNST of vehicle [solution of saline containing 30% of DMSO (DMSO), 100 nL] or the selective CB1 receptor antagonist AM251 (AM251, 100 pmol/100 nL). Circles represent the mean ± SEM. *P < 0.05 over the entire restraint period compared to SAL LH + DMSO BNST group. Two-way ANOVA accompanied by Bonferroni post-hoc test (n = 7/group). (Top, right) Mean Δ MAP and Δ HR during the entire restraint stress period in animals treated bilaterally into the LH with SAL (100 nL) or SR95531 (1 pmol/100 nL), followed by a second microinjection into the BNST of DMSO (100 nL) or AM251 (100 pmol/100 nL). Columns represent the mean and bars the SEM. *P < 0.05 in relation to SAL LH + DMSO BNST group. One-way ANOVA accompanied by Bonferroni post-hoc test (n = 7/group). (Bottom) Pulsatile arterial pressure (PAP), MAP and HR recordings before and during restraint stress of representative rats illustrating the effect of local LH treatment with saline (SAL) or the selective GABA_A receptor antagonist SR95531, followed by a second microinjection into the BNST of vehicle (DMSO) or the selective CB1 receptor antagonist AM251 (AM251). The arrows indicate the microinjection into the LH and BNST, respectively. Note the increase in restraint-evoked tachycardia in SAL LH + AM251 BNST group, which was inhibited when the LH was pretreated with the GABA_A receptor antagonist (SR95531 LH + AM251 BNST group).
We reported previously that microinjection of the selective CB1 receptor antagonist AM251 into the BNST dose-dependently enhanced the tachycardia (without affecting blood pressure and tail skin temperature responses) observed during acute session of restraint stress. Conversely, increase in either anandamide or 2-arachidonoyl-glycerol levels in the BNST decreased HR response to restraint stress, and the effect of both endocannabinoids were inhibited in animals pretreated in the BNST with AM251. These previous results support the present findings indicating an inhibitory role of CB1 receptors in restraint-evoked tachycardia.

CB1 receptors are expressed predominantly in presynaptic terminals. Accordingly, CB1 receptor was identified in both excitatory and inhibitory terminals onto BNST neurons, and its activation inhibited local glutamatergic and GABAergic inputs. However, CB1 receptor activation present in glutamatergic terminals seem to be prominent during aversive threats within the BNST. For instance, previous findings identified that CB1 receptor blockade enhanced stress-evoked c-fos mRNA in the BNST. Besides, we reported recently that the facilitated tachycardia to restraint stress following BNST treatment with AM251 was inhibited by local NMDA glutamate receptor antagonism within the BNST. The idea that control of cardiovascular responses to restraint by BNST CB1 receptor is mediated by interaction with local glutamatergic neurotransmission is further supported by evidence that BNST NMDA glutamate receptor plays a facilitatory influence in restraint-evoked HR response without affecting pressor and tail skin temperature changes.

Figure 3. Effect of lateral hypothalamus (LH) treatment with the selective GABAA receptor antagonist SR95531 and/or microinjection of the CB1 receptor antagonist AM251 into the bed nucleus of the stria terminalis (BNST) in drop in tail skin temperature evoked by an acute session of restraint stress. (Top, left) Time-course curves of changes in tail skin temperature (Δ tail temperature) evoked by acute restraint stress in animals treated bilaterally into the LH with saline (SAL, 100 nL) or the selective GABAA receptor antagonist SR95531 (1 pmol/100 nL), followed by a second microinjection into the BNST of vehicle [solution of saline containing 30% of DMSO (DMSO), 100 nL] or the selective CB1 receptor antagonist AM251 (AM251, 100 pmol/100 nL). Circles represent the mean ± SEM. Two-way ANOVA (n = 7/group). (Top, right) Mean Δ tail temperature during the entire restraint stress period in animals treated bilaterally into the LH with SAL (100 nL) or SR95531 (1 pmol/100 nL), followed by a second microinjection into the BNST of DMSO (100 nL) or AM251 (100 pmol/100 nL). Columns represent the mean and bars the SEM. One-way ANOVA (n = 7/group). (Bottom) Images of representative rats showing the tail skin temperature before and at first and last minute of restraint stress in animals treated with saline (SAL) or the selective GABAA receptor antagonist SR95531 into the LH, followed by a second microinjection of vehicle (DMSO) or the selective CB1 receptor antagonist AM251 into the BNST. Note the absence of effect of the pharmacological treatments.
Current data provide evidence regarding the neural circuit related to the control of tachycardia to restraint stress by BNST CB1 receptor by indicating a prominent role of projections to the LH. As stated in the Introduction, previous studies provided evidence of GABAergic inputs within the LH arising from the BNST. These neuroanatomical evidence, taken together with results mentioned above that CB1 receptor activation during aversive threats acts mainly inhibiting glutamatergic terminals during aversive threats, indicate that the decrease in number of Fos-immunoreactive cells in the LH observed in the present study in animals treated with the CB1 receptor antagonist in the BNST might be the resulted of an increased local glutamatergic neurotransmission, which in turn increase activation of BNST GABAergic neurons projecting to the LH. The hypothesis that GABAergic connection with the LH mediates the inhibitory control of BNST CB1 receptor was further supported by demonstration that LH pretreatment with the GABAa receptor antagonist SR95531 completely inhibited the facilitation of HR increase to restraint stress caused by BNST treatment with the CB1 receptor antagonist AM251. Therefore, the amplitude of the tachycardia evoked by acute stress exposure rely on CB1 receptor within the BNST governing reduction in GABAergic influence exerted by BNST upon LH neurons inhibiting heartbeat during stressful event. This idea is in line with recent report that GABAergic projections from the BNST to the LH have been previously implicated in behavioral responses, including feeding and anxiety-like behavior. However, this pathway seem not to be related to the control of cocaine conditioned place preference by LH orexin neurons. Besides, the decrease in anxiety-like behaviors evoked by stimulation of BNST-LH projection was not followed by changes in respiratory rate, which indicated that this neural network was not involved in physiological changes related to this behavioral response.

Figure 4. Schematic representation illustrating the proposed mechanism of interaction between BNST endocannabinoid neurotransmission acting via local CB1 receptor and GABAergic neurotransmission within the LH in the control of tachycardiac response during aversive threats. Activation of CB1 receptor in the BNST present in glutamatergic terminals (1) inhibits the local release of glutamate (2), which in turn decreases the activity of BNST GABA neurons (3) and, consequently, the release of GABA in the HL (4). The decreased GABA release increase activity of local HL neurons (5), which cause an inhibitory influence in HR increase during stressful events (6) (please, see the text for details). 2-AG 2-arachidonoylglycerol, AEA anandamide, BNST bed nucleus of the stria terminalis. Glu glutamate, HR heart rate.
Therefore, to the best of our knowledge, our findings are the first to indicate an involvement of the BNST-LH pathway in physiological responses during aversive threats43. Besides, in addition to provide evidence of the brain network involved in the control of cardiovascular responses by BNST endocannabinoid neurotransmission, results reported here also indicate a mechanism involved in neuronal activation within the LH during aversive threats.

GABAergic projections from the BNST targets glutamatergic neurons within the LH14. Previous studies identified inputs from the LH in parasympathetic brainstem nuclei44,45. Indeed, Deolindo et al.27 reported that cardiac parasympathetic activity governs the inhibitory control of restraint-evoked HR increase by the LH. Control of tachycardia to restraint by the BNST was also documented to be mediated by facilitation of parasympathetic nervous system5. Based on these pieces of evidence, it is possible that the inhibitory control of restraint-evoked HR increase by BNST CB1 receptors occurring via inhibition of GABAergic inputs within the LH is mediated by an increase in activity of LH glutamatergic neurons projecting to parasympathetic centers in the medulla. However, BNST projections also target neurons expressing orexin and melanin concentrating hormone (MCH) within the LH20. Although evidence that BNST GABAergic neurons inhibit MCH cells within the LH20, these neurons are inhibited by aversive stimuli20, which preclude the idea of a role of MCH cells in control of stress responses by BNST CB1 receptors. Orexin neurons also seem not to be part of the pathway proposed in the present study once this neurochemical mechanism in the brain plays a facilitatory influence in stress-evoked cardiovascular changes46–48, so that increased activity of LH orexin neurons would increase rather than decrease restraint-evoked HR increase. The absence of an involvement of orexin neurons is further supported by evidence that orexinergic mechanisms are not involved in cardiovascular changes caused by restraint47.

The idea that control of tachycardia to stress by BNST CB1 receptors is mediated by direct GABAergic projections to the LH is supported by evidence of the BNST as a prominent source of GABAergic inputs in the LH20,33. Besides, previous studies have indicated that optogenetic activation of BNST GABAergic terminals within the LH affected feeding and anxiety-like behaviors54,41. However, we cannot exclude the possibility that involvement of LH GABAergic neurotransmission in BNST CB1 receptor control of tachycardia to restraint stress is mediated by recruitment of intermediate brain regions. In fact, previous studies identified LH-projecting GABAergic neurons in brain regions that receive BNST inputs49–52 and are involved in control of stress-evoked cardiovascular responses53–55, such as amygdala and lateral preoptic area. Therefore, further studies are necessary to directly assess if control of cardiovascular responses to stress by BNST CB1 receptors are mediated by direct or indirect connections with the LH.

In summary, the results reported in the present study provide evidence of the LH as part of the neural network regulating the cardiovascular responses to aversive threats by BNST endocannabinoid neurotransmission. In fact, our data indicate that the inhibitory control related to CB1 receptors activation within the BNST in tachycardia to stress is mediated by LH GABAergic neurotransmission acting via local GABA receptors. Findings reported here also provide evidence that BNST endocannabinoid neurotransmission is potentially involved in activation of LH neurons during aversive threats.

Methods

Animals. Forty-seven male Wistar rats weighting 240–260 g (60-days-old) were used. Animals were obtained from the animal breeding facility of the São Paulo State University (UNESP) (Botucatu, SP, Brazil), and were housed according to conditions established in our laboratory13,28,56,57. Briefly, the rats were housed in plastic cages in a temperature-controlled room at 24 °C in the Animal Facility of the Laboratory of Pharmacology (School of Pharmaceutical Sciences/UNESP). They were kept under a 12:12 h light–dark cycle (lights on between 7:00 am and 7:00 pm) with free access to water and standard laboratory food. Housing conditions and experimental procedures were approved by the Ethical Committee for Use of Animals of the School of Pharmaceutical Sciences/UNESP (approval # 61/2015), which complies with Brazilian and international guidelines for animal use and welfare. The study was carried out in compliance with the ARRIVE guidelines.

Implant of brain cannulas. Five days before the trial, rats were anesthetized with tribromoethanol (250 mg/kg, i.p.). After scalp anesthesia with 2% lidocaine, the skull was exposed and stainless-steel guide cannulas (26 G, 12 mm-long) directed to the LH and/or BNST were bilaterally implanted at a position 1 mm above the site of injection, using a stereotaxic apparatus (Stoelting, Wood Dale, IL, USA). Stereotaxic coordinates for cannula implantation into the BNST were: antero-posterior = + 7.8 mm from interaural line; lateral = 4 mm from the medial suture; dorso-ventral = − 5.8 mm from the skull, with a lateral inclination of 23°58. For the LH, the stereotaxic coordinates were: antero-posterior = + 6.2 mm from interaural line; lateral = 1.8 mm from the medial suture; dorso-ventral = − 7.6 mm from the skull; without lateral angulation13. Cannulas were fixed to the skull with dental cement and one metal screw. After the surgery, all animals received a poly-anbiotic solution containing streptomycins and penicillins (560 mg/ml/kg, i.m.) to prevent infection and the non-steroidal anti-inflammatory flunixin meglumine (0.5 mg/ml/kg, s.c.) for post-operation analgesia.

Cannulation of femoral artery. One day before the trial, rats were anesthetized with tribromoethanol (250 mg/kg, i.p.), and a catheter (Clay Adams, Parsippany, NJ, USA) filled with a solution of heparin (50UI/ml, Hepamax-S, Blausiegel, Cotia, SP, Brazil) diluted in saline (0.9% NaCl) was inserted into the abdominal aorta through the femoral artery for cardiovascular recording, according to procedures previously described by our group35,57,59,61. After the surgery, the non-steroidal anti-inflammatory flunixin meglumine (0.5 mg/ml/kg, s.c.) was administered for post-operation analgesia. The animals were kept in individual cages during the postoperative period and cardiovascular recording.
Restraint stress. The acute restraint stress consisted of introducing the animals into plastic cylindrical tubes (diameter = 6.5 cm, length = 15 cm), which were ventilated by ½ inch holes that comprised approximately 20% of the tube, as previously described by us5,13. The animals were maintained for a period of 60 min into the restraint tube5,13,27. Each animal was submitted to only one session of stress in order to avoid habituation5,13,43.

Blood pressure and heart rate recording. The catheter implanted into the femoral artery was connected to a pressure transducer (DPT100, Utah Medical Products Inc., Midvale, UT, USA); and pulsatile arterial pressure (PAP) was recorded using an amplifier (Bridge Amp, ML224, ADInstruments, Australia) and an acquisition board (PowerLab 4/30, ML866/IP, ADInstruments, NSW, Australia) connected to a personal computer, as previously described by us33,57,64,65. Mean arterial pressure (MAP) and HR values were derived from the PAP recording.

Tail cutaneous temperature measurement. Vasomotor sympathetic activity activation during aversive threats decreases cutaneous blood flow66 that in turn reduces cutaneous temperature67. Therefore, the drop in tail cutaneous temperature was evaluated as an indirect measurement of vasomotor sympathetic response in cutaneous beds during restraint stress13,35,67.

The tail cutaneous temperature was recorded using a thermal camera (IRI4010, Infra Red Integrated Systems Ltd., Northampton, UK). The analysis was performed using a software for thermographic analysis, and temperature was represented by color intensity variations67,68. For image analysis, the temperature was measured on five points along the animal’s tail, and the mean value was calculated for each recording13,35,39,69.

Drug microinjection. The needles (33G, Small Parts, Miami Lakes, FL, USA) used for microinjection into the BNST and/or LH were 1 mm longer than the guide cannulas and were connected to a 2 μL syringe (7002-KH, Hamilton Co., Reno, NV, USA) via a PE-10 tubing (Clay Adams, Parsippany, NJ, USA). Intra-cerebral microinjections were performed within a 5 s period, and the needle was left in the guide cannula for 1 min after the microinjection before being removed. Microinjection was performed without restraining the animals, and drugs were administrated into the LH and BNST in a final volume of 100 nL per side5,13,27,28,67.

Drugs and solutions. SR95531 (selective GABA_A receptor antagonist) (TOCRIS, West-woods Business Park, Ellisville, MO, USA; cat. #1262), 2,2,2-tribromoethanol (Sigma-Aldrich, St Louis, Missouri, USA; cat. #T48402) and urethane (Sigma-Aldrich; cat. #U2500) were dissolved in saline (NaCl 0.9%). AM251 (N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlo-rophenyl)-4-methyl-1H-pyrazole-3 carboxamide) (selective CB receptor antagonist) (TOCRIS, cat. #1117) was dissolved in a solution of saline containing 30% of DMSO (DMSO). Flunixin meglumine (Banamine, Schering Ploug, Cotia, SP, Brazil) and the polyanthbiotic preparation of streptomycins and penicillins (Pentabiotico, Fort Dodge, Campinas, SP, Brazil) were used as provided.

Immunohistochemistry. Thirty minutes after the end of the stress session, the animals were anesthetized with urethane (1.2 g/kg, i.p.) and perfused with saline phosphate (PBS) (1X pH 7.4) accompanied by 4% paraformaldehyde in solution with phosphate buffer (pH 7.4). Then, the brain was removed and post-fixed in paraformaldehyde for 2 h and transferred to 30% sucrose solution in PBS at 4 °C. Two days later, the brains were frozen in dry ice powder for 1 h, and then stored in freezer at −80 °C until processing.

Before the immunohistochemistry procedures, the brains were sectioned in a cryostat (~ 20 °C) (CM1900, Leica, Germany) with a thickness of 35 μm according to coordinates of Paxinos and Watson58. The slices containing the LH region were washed 3 times (10 min each wash) in PBS and incubated in blocking solution (3% goat serum and 0.25% Triton X-100) dissolved in PBS for one hour at room temperature. After the blockage, the slices were incubated with anti- Fos primary antibody (1:2000 dilution; Cell Signaling Technology, Danvers, MA, USA; produced in rabbit) for 24 h at 4 °C. The slices were washed with PBS 3 times (10 min each wash) and incubated with biotinylated anti-rabbit secondary antibody (dilution 1:600; Vector Laboratories, Burlingame, CA, USA) in PBS-Tx (0.25% Triton X-100) and 3% goat serum for 2 h at room temperature. The slices were then washed with PBS 3 times (10 min each wash) and incubated for 1 h in avidin–biotin-peroxidase solution (ABC Elite kit, PK-6100; Vector Laboratories, Burlingame, CA, USA), 0.5% Triton X-100 and PBS. The slices were then washed 3 times (10 min each wash) and incubated in 3,3′-diaminobenzidine (DAB) for seven min. Then, they were washed 4 times (5 min each wash), transferred to PBS solution and mounted on gelatinized slides. After drying, the slides were hydrated in distilled water and then gradient dehydrated by increasing ethanol titrations (30%, 60%, 90%, 95% and 100%) and xyloc (LabSynth, São Paulo, Brazil). Finally, they were covered with Permount (Sigma-Aldrich, St. Louis, MA, USA) and coverslips.

Immunostaining of Fos was captured in a microscope coupled to a camera (Zeiss Axioskop 2). Two images were captured per slice (right and left hemispheres) and at least two slices were obtained per animal, and the counting was performed from a fixed area of the LH. The Fos-positive cells were counted using the ImageJ software (version 1.52q website: https://imagej.nih.gov/ij/download.html). The results were expressed as mean number of Fos-positive cells/mm2. The LH was identified according to the atlas of rat’s brain of Paxinos and Watson58.

Experimental design. Experimental procedures were as previously described by us13,35,70. Briefly, animals were brought to the experimental room in their own cages. Animals were allowed at least 60 min to adapt to the experimental room conditions, such as sound and illumination, before starting the experiments. The experimental room was temperature controlled (24 °C) and acoustically isolated from the other rooms.
Effect of CB1 receptor blockade within the BNST on number of Fos-positive neurons in the LH of stressed animals. This protocol aimed to test the hypothesis that antagonism of CB1 receptor within the BNST decreases the number of Fos-positive neurons in the LH during restraint stress. For this, animals were treated with either vehicle (saline containing 30% of DMSO, 100 nL/side, n = 8) or the selective CB1 receptor antagonist AM251 (100 pmol/100 nL/side, n = 11) into the BNST. Ten min after the treatment, all rats were submitted to a 60 min session of restraint stress. Thirty minutes after the end of the stress session, the animals were anesthetized with urethane (1.2 g/kg, i.p.), perfused, and their brains were processed for immunohistochemistry protocol.

Effect GABAA receptor antagonism in the LH in changes of cardiovascular and tail skin temperature reactivity to acute restraint stress evoked by CB1 receptor blockade in the BNST. The aim of this protocol was to evaluate the involvement GABAergic neurotransmission in the LH, acting via local GABAA receptors, in changes of restraint-evoked MAP and HR increase and drop in tail skin temperature caused by CB1 receptor antagonist in the BNST. For this, independent sets of rats were pretreated into the LH with either the selective GABAA receptor antagonist SR95531 (1 pmol/100 nL) or vehicle (saline, 100 nL/side)28. Five minutes later, the animals received either vehicle (saline containing 30% of DMSO, 100 nL/side) or AM251 (100 pmol/100 nL/side) into the BNST (n = 7/group, Table 1)13,35. Five minutes after the second pharmacological treatment, animals in all experimental groups underwent a 60 min session of restraint stress.

Blood pressure and HR recording started at least 30 min before the onset of the restraint, and was performed throughout the stress session. The tail skin temperature was measured 10, 5 and 0 min before the restraint for baseline values, and at 10, 20, 40 and 60 min during restraint13,35. Each animal received a single pharmacological treatment and was submitted to one session of restraint. In each protocol, animals were randomly distributed among the several experimental groups.

Histological determination of the microinjection sites. At the end of each experiment, animals were anesthetized with urethane (1.2 g/kg, i.p.), and 1% Evan's blue dye was microinjected into the brain at the same volume of drug injection (i.e.,100 nL/side) as a marker of microinjection site. Then, the brains were removed and post-fixed in 10% formalin solution for at least 48 h at 4 °C. Afterwards, serial 40 μm thick sections of the BNST region were cut using a cryostat (CM1900, Leica, Wetzlar, Germany) for identification of the microinjection sites according to Paxinos and Watson58.

Photomicrographs of coronal brain sections depicting bilateral microinjection sites in the LH and BNST of representative animals are presented in Fig. 5. Diagrammatic representations based on the brain atlas of Paxinos and Watson58 indicating the microinjection sites into the LH and BNST of all animals used in the present study are also presented in Fig. 5.

Data analysis. Data were expressed as mean ± SEM. The number of Fos-positive cells in the LH were compared using the Student's t-test. The basal values of MAP, HR and tail skin temperature were compared using one-way ANOVA followed by Bonferroni's post-hoc test. Restraint-evoked cardiovascular changes were obtained by...
calculating the difference between the values recorded during the restraint stress and the baseline value obtained by the mean of points recorded across the 10 min before the restraint onset. The time-course curves of MAP, HR and tail skin temperature changes were analyzed using two-way ANOVA, with treatment as main factor and time as repeated measurement, followed by the Bonferroni’s post-hoc test. The mean of the values during the entire restraint session was also calculated, and these values were compared using one-way ANOVA followed by Bonferroni’s post-hoc test. Results of statistical tests with P < 0.05 were considered significant.

Data availability
Data available on request from the authors.

Received: 13 May 2021; Accepted: 26 July 2021
Published online: 09 August 2021

References
1. Crestani, C. et al. Mechanisms in the bed nucleus of the stria terminalis involved in control of autonomic and neuroendocrine functions: A review. Curr. Neuropharmacol. 11, 141–159 (2013).
2. Myers, B. Corticolimbic regulation of cardiovascular responses to stress. Physiol. Behav. 172, 49–59 (2017).
3. Radley, J. J. & Johnson, S. B. Anteroventral bed nucleus of the stria terminalis neurocircuitry: Towards an integration of HPA axis modulation with coping behaviors—Curt Richter Award Paper 2017. Psychoneuroendocrinology 89, 239–249 (2018).
4. Resstel, L. B. M. et al. Anxiolytic-like effects induced by acute reversible inactivation of the bed nucleus of stria terminalis. Neuroscience 154, 869–876 (2008).
5. Crestani, C. C., Alves, F. H. F., Tavares, R. F. & Corrêa, F. M. A. Role of the bed nucleus of the stria terminalis in the cardiovascular responses to acute restraint stress in rats. Stress 12, 268–278 (2009).
6. Crestani, C. C., Alves, F. H. F., Resstel, L. B. M. & Correa, F. M. A. The bed nucleus of the stria terminalis modulates exercise-evoked cardiovascular responses in rats. Exp. Physiol. https://doi.org/10.1113/expphysiol.2009.049056 (2010).
7. Ching, S., Fu, J., Brown, R. M., McDougall, S. J. & Lawrence, A. J. The intersection of stress and reward: BNST modulation of aversive and appetitive states. Prog. Neuro-Pharmacol. Biol. Psychiatry 87, 108–125 (2018).
8. Bedse, G., Centanni, S. W., Winder, D. G. & Patel, S. Endocannabinoid signaling in the central amygdala and bed nucleus of the stria terminalis: Implications for the pathophysiology and treatment of alcohol use disorder. Alcohol. Clin. Exp. Res. 43, 2014–2027 (2019).
9. Matsuda, L. A., Bonner, T. I. & Lollait, S. J. Localization of cannabinoid receptor mRNA in rat brain. J. Comp. Neurol. 327, 535–550 (1993).
10. Tsou, K., Brown, S., Sáñudo-Peña, M. C., Mackie, K. & Walker, J. M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83, 393–411 (1998).
11. Gomes-de-Souza, L. et al. CB1 and CB2 receptors in the bed nucleus of the stria terminalis differently modulate anxiety-like behaviors in rats. Prog. Neuro-Psychopharmacology Biol. Psychiatry 110, 110284 (2021).
12. Gulyás, A. L. et al. Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and post-synaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur. J. Neurosci. 20, 441–458 (2004).
13. Gomes-de-Souza, L. et al. Involvement of endocannabinoid neurotransmission in the bed nucleus of stria terminalis in cardiovascular responses to acute restraint stress in rats. Br. J. Pharmacol. 173, 2833–2844 (2016).
14. Puente, N. et al. Localization and function of the cannabinoid CB1 receptor in the anterolateral bed nucleus of the stria terminalis. PLoS ONE 5, e8689 (2010).
15. Puente, N. et al. Polymodal activation of the endocannabinoid system in the extended amygdala. Nat. Neurosci. 14, 1542–1547 (2011).
16. Newsom, R. J. et al. Cannabinoid receptor type 1 antagonism significantly modulates basal and loud noise induced neural and hypothalamic-pituitary-adrenal axis responses in male Sprague-Dawley rats. Neuroscience 204, 64–73 (2012).
17. Newsom, R. J. et al. Remote CB1 receptor antagonist administration reveals multiple sites of tonic and phasic endocannabinoid neuroendocrine regulation. Psychoneuroendocrinology 113, 104549 (2020).
18. Lange, M. D. et al. Cannabinoid CB1 receptors in distinct circuits of the extended amygdala determine fear responsiveness to unpredictable threat. Mol. Psychiatry 22, 1422–1430 (2017).
19. Hosoya, Y. & Matsushita, M. Cells of origin of the descending afferents to the lateral hypothalamic area in the rat, studied with the horseradish peroxidase method. Neurosci. Lett. 383, 231–236 (1980).
20. González, J. A., Jordaniou, P., Strom, M., Adamantidis, A. & Bundakov, D. Awake dynamics and brain-wide direct inputs of hypthalamic MCH and orexin networks. Nat. Commun. 7, 11395 (2016).
21. Mu, M.-D. et al. A limbic circuitry involved in emotional stress-induced grooming. Nat. Commun. 11, 2261 (2020).
22. Carrive, P. Orexin, stress and central cardiovascular control: A link with hypertension? Neurosci. Biobehav. Rev. 74, 376–392 (2017).
23. Soya, S. & Sakurai, T. Orexin as a modulator of fear-related behavior: Hypothalamic control of noradrenaline circuit. Brain Res. 1731, 146037 (2020).
24. Johnson, P. L., Molosh, A., Fitz, S. D., Truitt, W. A. & Shekhar, A. Orexin, stress, and anxiety/panic states. Prog. Brain Res. 198, 133–161 (2012).
25. Iwata, J., LeDoux, J. E. & Reis, D. J. Destruction of intrinsic neurons in the lateral hypothalamic nucleus disrupts the classical conditioning of autonomic but not behavioral emotional responses in the rat. Brain Res. 368, 161–166 (1986).
26. LeDoux, J. E., Iwata, J., Cicchetti, P. & Reis, D. J. Different projections of the central amygdaloid nucleus mediate autonomic and behavioral correlates of conditioned fear. J. Neurosci. https://doi.org/10.1523/jneurosci.1001-06.2006 (1988).
27. Deolindo, M. V. et al. NMDA receptors in the lateral hypothalamus have an inhibitory influence on the tachycardiac response to acute restraint stress in rats. Eur. J. Neurosci. 38, 2374–2381 (2013).
28. Gomes-de-Souza, L., Bennini, R., Costa-Ferreira, W. & Crestani, C. C. GABA and non-GABAB receptors in the lateral hypothalamus modulate the tachycardic response to emotional stress in rats. Eur. Neuropsychopharmacol. 29, 672–680 (2019).
29. Cullinan, W. E., Herman, J. P. & Watson, S. J. Ventral subicular interaction with the hypothalamic paraventricular nucleus: evidence for a relay in the bed nucleus of the stria terminalis. J. Comp. Neurol. 332, 1–20 (1993).
30. Radley, J. J., Gosselin, K. L. & Sawchenko, P. E. A discrete GABAergic relay mediates medial prefrontal cortical inhibition of the neuroendocrine stress response. J. Neurosci. 29, 7330–7340 (2009).
31. Kudo, T. et al. Three types of neurochemical projection from the bed nucleus of the stria terminalis to the ventral tegmental area in adult mice. J. Neurosci. 32, 18035–18046 (2012).
32. Poulin, J.-F., Arbour, D., Lafort, S. & Drolet, G. Neuroanatomical characterization of endogenous opioids in the bed nucleus of the stria terminalis. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 33, 1356–1365 (2009).
33. Gritt, I., Mainville, L. & Jones, R. E. Projections of GABAergic and cholinergic basal forebrain and GABAergic preoptic-anterior hypothalamic neurons to the posterior lateral hypothalamus of the rat. J. Comp. Neurol. 339, 251–268 (1994).
34. Jennings, J. H., Rizzi, G., Stamatakis, A. M., Ung, R. L. & Stuber, G. D. The inhibitory circuit architecture of the lateral hypothalamus orchestrates feeding. Science 341, 1517–1521 (2013).
35. Gomes-de-Souza, L., Costa-Ferreira, W., Oliveira, L. A., Benini, R. & Crestani, C. C. Cannabinoid receptor type 1 in the bed nucleus of the stria terminals modulates cardiovascular responses to stress via local N-methyl-D-aspartate receptor/neuronal nitric oxide synthase/guanylate cyclase/protein kinase G signaling. J. Psychopharmacol. 34, 429–440 (2020).
36. Katona, I. & Freund, T. F. Multiple functions of endocannabinoid signaling in the brain. Annu. Rev. Neurosci. 35, 529–558 (2012).
37. Mechoulam, R. & Parker, L. A. The endocannabinoid system and the brain. Annu. Rev. Psychol. 64, 21–47 (2013).
38. Araque, A., Castillo, P. E., Manzoni, O. J. & Tonini, R. Synaptic functions of endocannabinoid signaling in health and disease. Neuropharmacology 124, 13–24 (2017).
39. Adami, M. B., Barretto-De-Souza, L., Duarte, J. O., Almeida, J. & Crestani, C. C. Both N-methyl-D-aspartate and non-N-methyl-D-aspartate glutamate receptors in the bed nucleus of the stria terminals modulate the cardiovascular responses to acute restraint stress in rats. J. Psychopharmacol. 31, 674–681 (2017).
40. Barretto-de-Souza, L., Adami, M. B., Benini, R. & Crestani, C. C. Dual role of nitrergic neurotransmission in the bed nucleus of the stria terminals in controlling cardiovascular responses to emotional stress in rats. Br. J. Pharmacol. 173, 3773–3783 (2018).
41. Kim, S.-Y. et al. Diverging neural pathways assemble a behavioural state from separable features in anxiety. Nature 496, 219–223 (2013).
42. Sartor, G. C. & Aston-Jones, G. Regulation of the ventral tegmental area by the bed nucleus of the stria terminalis is required for expression of cocaine preference. J. Eur. Neurol. 36, 3549–3558 (2012).
43. Kim, S.-R. & Kim, S.-Y. Functional dissection of glutamatergic and GABAergic neurons in the bed nucleus of the stria terminalis. Mol. Cells https://doi.org/10.14348/molcells.2021.0006 (2021).
44. Luiten, P. G. M., ter Horst, G. J. & Steffens, A. B. The hypothalamus, intrinsic connections and outflow pathways to the endocrine system in relation to the control of feeding and metabolism. Prog. Neurobiol. 28, 1–54 (1987).
45. ter Horst, G. J., Luiten, P. G. M. & Kuipers, F. Descending pathways from hypothalamus to dorsal motor vagus and ambiguus nuclei in the rat. J. Auton. Nerv. Syst. 11, 59–75 (1984).
46. Beig, M. I., Dampney, B. W. & Carrive, P. Both Ox1r and Ox2r orexin receptors contribute to the cardiovascular and locomotor components of the novelty stress response in the rat. Neuropharmacology 89, 146–156 (2015).
47. Furlong, T. M., Vianna, D. M. L., Liu, L. & Carrive, P. Hypocretin/orexin contributes to the expression of some but not all forms of stress and arousal. Eur. J. Neurosci. 30, 1603–1614 (2009).
48. Kayaba, Y. et al. Attenuated defense response and low basal blood pressure in orexin knockout mice. Am. J. Physiol. Integr. Comp. Physiol. 285, R581–R593 (2003).
49. Wayner, M. J., Barone, F. C., Scharoun, S. L., Guevara-Aguilar, R. & Aguilar-Batouroni, H. U. Limbic connections to the lateral preoptic area: A horseradish peroxidase study in the rat. Neurosci. Biobehav. Rev. 7, 375–384 (1983).
50. Dong, H. W. & Swanson, L. W. Projections from bed nucleus of the stria terminals, anteromedial area: Cerebral hemisphere integration of onofnordocine, autonomic, and behavioral aspects of energy balance. J. Comp. Neurol. 494, 142–178 (2006).
51. Myers, B., Mark Dolgus, C., Kaschow, J., Cullinan, W. E. & Herman, J. P. Central stress-inactivating circuits: Forebrain glutamatergic and GABAergic projections to the dorsomedial hypothalamus, medial preoptic area, and bed nucleus of the stria terminalis. Brain Struct. Funct. 219, 1287–1303 (2014).
52. Liu, J. et al. Differential efferent projections of GABAergic neurons in the basolateral and central nucleus of amygdala in mice. Neurosci. Lett. 745, 10 (2021).
53. Fortaleza, E. A. T., Tavares, R. F. & Corrêa, F. M. A. The medial amygdaloid nucleus modulates cardiovascular responses to acute restraint in rats. Neuroscience 159, 717–726 (2009).
54. Duarte, J. O., Gomes, K. S., Nunes-de-Souza, R. L. & Crestani, C. C. Role of the lateral preoptic area in cardiovascular and neuroendocrine responses to acute restraint stress in rats. Physiol. Behav. 175, 16–21 (2017).
55. Sanders, B. J., Wirtz-Nole, C., DeFord, S. M. & Erling, B. F. Central amygdaloid lesions attenuate cardiovascular responses to acute stress in rats with borderline hypertension. Physiol. Behav. 56, 709–713 (1994).
56. Duarte, J. O., Cruz, F. C., Leão, R. M., Planeta, C. S. & Crestani, C. C. Stress vulnerability during adolescence. Psychosom. Med. 77, 186–199 (2015).
57. Almeida, J., Duarte, J. O., Oliveira, L. A. & Crestani, C. C. Effects of nitric oxide synthesis inhibitor or fluoxetine treatment on depression-like state and cardiovascular changes induced by chronic variable stress in rats. Stress 18, 462–474 (2015).
58. Paxinos, G. & Watson, C. The Rat Brain in Stereotaxic Coordinates 3rd edn. (Academic Press, 1997).
59. Costa-Ferreira, W., Vieira, J. O., Almeida, J., Gomes-de-Souza, L. & Crestani, C. C. Involvement of type 1 angiotensin II receptor (AT1) in cardiovascular changes induced by chronic emotional stress: Comparison between homotypic and heterotypic stressors. Front. Pharmacol. 7, 262 (2016).
60. Costa-Ferreira, W., Gomes-de-Souza, L. & Crestani, C. C. Role of angiotensin receptors in the medial amygdaloid nucleus in autonomic, baroreflex and cardiovascular changes evoked by chronic stress in rats. Eur. J. Neurosci. 33, 763–777 (2021).
61. Benini, R., Oliveira, L. A., Gomes-de-Souza, L. & Crestani, C. C. Habituation of the cardiovascular responses to restraint stress in male rats: Influence of length, frequency and number of aversive sessions. Stress 22, 151–161 (2019).
62. Santos, C. E., Benini, R. & Crestani, C. C. Spontaneous recovery, time course, and circadian influence on habituation of the cardiovascular responses to repeated restraint stress in rats. Pflugers Arch. Eur. J. Physiol. 472, 1495–1506 (2020).
63. Benini, R., Oliveira, L. A., Gomes-de-Souza, L. & Rodregues, B. R. & Crestani, C. C. Habitation of the cardiovascular responses to restraint stress is inhibited by exposure to other stressor stimuli and exercise training. J. Exp. Biol. https://doi.org/10.1242/jeb.219501 (2020).
64. Almeida, J., Oliveira, L. A., Benini, R. & Crestani, C. C. Role of hippocampal nitricergic neurotransmission in behavioral and cardiovascular dysfunctions evoked by chronic social stress. Nitric Oxide 94, 114–124 (2020).
65. Costa-Ferreira, W., Gomes-de-Souza, L. & Crestani, C. C. AT2 and MAS (but not AT1) angiotensin receptors in the medial amygdaloid nucleus modulate the baroreflex activity in rats. Pflugers Arch. Eur. J. Physiol. 471, 1173–1182 (2019).
66. Blessing, W. W. Lower brainstem pathways regulating sympathetically mediated changes in cutaneous blood flow. Cell. Mol. Neurobiol. 23, 527–538 (2003).
67. Vianna, D. M. L. & Carrive, P. Changes in cutaneous and body temperature during and after conditioned fear to context in the rat. Eur. J. Neurosci. 21, 2305–2312 (2005).
68. Buzardo, M. C. et al. Nitricergic neurotransmission in the paraventricular nucleus of the hypothalamus modulates autonomic, neuroendocrine and behavioral responses to acute restraint stress in rats. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 90, 16–27 (2019).
69. Barretto-de souza, L., Benini, R., Reis-silva, L. L. & Crestani, C. C. Corticotropin-releasing factor neurotransmission in the lateral hypothalamus modulates the tachycardiac response during acute emotional stress in rats. Brain Res. Bull. 166, 102–109 (2021).
70. Oliveira, L. A., Gomes-de-Souza, L., Benini, R. & Crestani, C. C. Control of cardiovascular responses to stress in CRF in the bed nucleus of stria terminalis is mediated by local NMDA/nNOS/sGC/PKG signaling. Psychoneuroendocrinology 89, 168–176 (2018).
Acknowledgements
This work was supported by grant from FAPESP (Grants # 2017/19249-0 and 2019/24478-3), CNPq (Grant # 431339/2018-0) and Scientific Support and Development Program of School of Pharmaceutical Sciences (UNESP). This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brasil (CAPES)—Finance Code 001. LGS and WCF were FAPESP PhD fellows (Process # 2016/05028-9 and 2016/05218-2). MMM is CAPES PhD fellow. CCC and CHX are CNPq research fellows (Process # 304108/2018-9 and 406393/2018-4, respectively).

Author contributions
L.G.S.: Conceptualization, Methodology, Formal analysis, Investigation, Writing—Original Draft, Visualization. W.C.F.: Formal analysis, Investigation, Writing—Review & Editing. M.M.M.: Formal analysis, Investigation, Writing—Review & Editing. C.H.X.: Formal analysis, Investigation, Resources, Writing—Review & Editing, Supervision. C.C.C.: Conceptualization, Methodology, Resources, Data Curation, Writing—Review & Editing, Visualization, Supervision, Project administration, Funding acquisition.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to C.C.C.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021